UCSF recruits NVIDIA to study AI in radiology

The University of California San Francisco (UCSF) is developing a new center dedicated to applying AI to the field of radiology and improving patient outcomes.

The UCSF Center for Intelligent Imaging, named ci2 for short, will be focused on using AI to “devise powerful new ways to look inside the body and to evaluate health and disease,” according to a news release on the UCSF website.

UCSF is also partnering with NVIDIA, a Santa Clara, California-based AI technology company, to develop new solutions at ci2 that can help providers adopt AI within their own practices. The center will use datasets from UCSF Health and other institutions to “develop, test and validate” its deep learning algorithms, taking advantage of new technology developed by NVIDIA.  

“Artificial intelligence represents the next frontier for diagnostic medicine,” Christopher Hess, MD, PhD, chair of the UCSF department of radiology and biomedical imaging, said in the news release. “It is poised to revolutionize the way in which imaging is performed, interpreted and used to direct care for patients.”

“AI is one of the greatest tools of this century,” Abdul Hamid Halabi, director of healthcare at NVIDIA, said in the same release. “ci2 is bringing together an innovative ecosystem of startups, vendors, UCSF’s thought leadership in radiology, and NVIDIA’s Clara platform on the world’s fastest GPUs, to create imaging AI solutions for improving patient care.”

Michael Walter
Michael Walter, Managing Editor

Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.